The disclosure relates to the use of an active substance known from human medicine for the treatment of gout in the preparation of a medicament for the treatment of laminitis, laminitis associated pain and/or laminitis-associated inflammation in equids (horses), wherein the medicament contains at least allopurinol, or allopurinol and cortisol or powdered opium as active substance.